Literature DB >> 19018962

Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus.

M De Kwaadsteniet1, K T Doeschate, L M T Dicks.   

Abstract

AIMS: To determine the antimicrobial activity of nisin F against Staphylococcus aureus in the respiratory tract. METHODS AND
RESULTS: The respiratory tract of nonimmunosuppressed and immunosuppressed Wistar rats were colonized with 4 x 10(5) viable cells of S. aureus K and then treated by administering 8192 arbitrary units (AU) nisin F intranasal. Symptoms of pneumonia were detected in the trachea and lungs of immunosuppressed rats that had not been treated with nisin F. The trachea and lungs of immunosuppressed rats treated with nisin F were healthy. No significant differences were recorded in blood cell indices. The antimicrobial activity of low concentrations nisin F (80-320 AU ml(-1)) was slightly stimulated by lysozyme and lactoferrin.
CONCLUSIONS: Nisin F inhibited the growth of S. aureus K in the respiratory tract of immunocompromised rats. Treatment with nisin F at 8192 AU proofed safe, as the trachea, lungs, bronchi and haematology of the rats appeared normal. SIGNIFICANCE AND IMPACT OF THE STUDY: Nisin F is nontoxic and may be used to control respiratory tract infections caused by S. aureus. This is, however, a preliminary study with an animal model and need to be confirmed with studies on humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018962     DOI: 10.1111/j.1472-765X.2008.02488.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  37 in total

1.  A Simple Method for the Purification of Nisin.

Authors:  Ronan Gough; Beatriz Gómez-Sala; Paula M O'Connor; Mary C Rea; Song Miao; Colin Hill; André Brodkorb
Journal:  Probiotics Antimicrob Proteins       Date:  2017-09       Impact factor: 4.609

Review 2.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

Review 3.  Anti-infective properties of bacteriocins: an update.

Authors:  Riadh Hammami; Benoit Fernandez; Christophe Lacroix; Ismail Fliss
Journal:  Cell Mol Life Sci       Date:  2012-10-30       Impact factor: 9.261

Review 4.  An expanding universe of small proteins.

Authors:  Errett C Hobbs; Fanette Fontaine; Xuefeng Yin; Gisela Storz
Journal:  Curr Opin Microbiol       Date:  2011-02-20       Impact factor: 7.934

Review 5.  Biochemical Features of Beneficial Microbes: Foundations for Therapeutic Microbiology.

Authors:  Melinda A Engevik; James Versalovic
Journal:  Microbiol Spectr       Date:  2017-10

6.  The Effects of Continuous In Vivo Administration of Nisin on Staphylococcus aureus Infection and Immune Response in Mice.

Authors:  A M Brand; C Smith; L M T Dicks
Journal:  Probiotics Antimicrob Proteins       Date:  2013-12       Impact factor: 4.609

7.  Evaluation of Nisin F in the Treatment of Subcutaneous Skin Infections, as Monitored by Using a Bioluminescent Strain of Staphylococcus aureus.

Authors:  M de Kwaadsteniet; C A van Reenen; L M T Dicks
Journal:  Probiotics Antimicrob Proteins       Date:  2009-08-13       Impact factor: 4.609

8.  Release of Enterococcus mundtii Bacteriocin ST4SA from Self-Setting Brushite Bone Cement.

Authors:  Anton D van Staden; Tiaan D J Heunis; Leon M T Dicks
Journal:  Probiotics Antimicrob Proteins       Date:  2011-06       Impact factor: 4.609

9.  Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored by In Vivo Bioluminescent Imaging.

Authors:  Anton Du Preez van Staden; Tiaan Heunis; Carine Smith; Shelly Deane; Leon M T Dicks
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  In vivo activities of recombinant divercin V41 and its structural variants against Listeria monocytogenes.

Authors:  Jitka Rihakova; Jean-Michel Cappelier; Isabelle Hue; Katerina Demnerova; Michel Fédérighi; Hervé Prévost; Djamel Drider
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.